EUVIMEDEUVIMED entdecken
Crossref

177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide

Sushree Arpitabala Yadav, V Kusum Vats, Rohit Sharma, Nitish Chauhan, Mahesh Subramanian, Amit Das, Drishty Satpati

Bioorganic & Medicinal Chemistry · 2024

DOI: 10.1016/j.bmc.2024.117883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2024. Verfasst von Sushree Arpitabala Yadav und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India. Hauptthemen laut MEDLINE: Lutetium, Erb-b2 Receptor Tyrosine Kinases, Nuclear Localization Signals, Radioisotopes. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tagging of cell permeable nuclear localization sequence (NLS) with receptor targeting peptide vectors is an attractive strategy for selectively targeted translocation of therapeutic cargoes. The present study aimed at grafting nuclear localization sequence (NLS) onto breast cancer targeting rL-A9 peptide. Molecular docking analysis revealed higher binding affinity of the peptide, DOTA-NLS-rL-A9 (-26.1 kJ/mol) towards HER2 receptor in comparison to DOTA-rL-A9 peptide (-22.2 kJ/mol). Confocal microscopy data suggested significantly enhanced cellular internalization of NLS-tagged peptide. The engineered HER2-selective, DOTA-NLS-rL-A9 peptide scaffold was radiolabeled with Lu-177 for intracellular delivery of the theranostic radionuclide into tumor cells. [177Lu]Lu-DOTA-NLS-rL-A9 exhibited significantly enhanced binding affinity (4.58 ± 1.77 nM) towards human breast carcinoma SKBR3 cells and cellular internalization (85 % at 24 h) compared to its original analog, [177Lu]Lu-DOTA-rL-A9. In vivo biodistribution studies showed consistent retention of [177Lu]Lu-DOTA-NLS-rL-A9 in the tumor with negligible washout of radioactivity (∼4.1 % ID/g at 48 h). Prolonged tumor activity with rapid off-target tissue clearance resulted in significantly high tumor-to-background ratios. The radiopeptide, [177Lu]Lu-DOTA-NLS-rL-A9 thus, being precisely confined into HER2-expressing tumor cells and exhibiting favourable pharmacokinetic features is an efficient candidate for further screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumErb-b2 Receptor Tyrosine KinasesNuclear Localization SignalsRadioisotopesHumansAnimalsMiceFemalePeptidesCell Line, TumorBreast NeoplasmsMolecular Docking SimulationRadiopharmaceuticalsTissue Distribution

Stichwörter der Autor:innen

A9 peptideHER2InternalizationLu-177NLS

Substanzen

LutetiumErb-b2 Receptor Tyrosine KinasesNuclear Localization SignalsRadioisotopesPeptidesRadiopharmaceuticalsLutetium-177ERBB2 protein, human

Autor:innen und Institutionen

  • Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.
  • Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India.
  • Bio-organic Division, Bhabha Atomic Research Centre, Mumbai, India.
  • Protein Crystallography Section, Bio-Science Group, Bhabha Atomic Research Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India.
  • Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address: drishtys@barc.gov.in.

Zitieren

APA

Yadav, S. A., Vats, V. K., Sharma, R., Chauhan, N., Subramanian, M., Das, A., & Satpati, D. (2024). 177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2024.117883

Vancouver

Yadav SA, Vats VK, Sharma R, Chauhan N, Subramanian M, Das A, et al. 177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide. Bioorganic & Medicinal Chemistry. 2024. doi:10.1016/j.bmc.2024.117883

BibTeX
@article{Yadav2024,
  author = {Yadav, Sushree Arpitabala and Vats, V Kusum and Sharma, Rohit and Chauhan, Nitish and Subramanian, Mahesh and Das, Amit and Satpati, Drishty},
  title = {177Lu-labeling of nuclear localization sequence (NLS)-grafted HER2-receptor affine peptide},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2024},
  doi = {10.1016/j.bmc.2024.117883}
}
Kostenlos starten →